【発明の名称】炎症を治療するための医薬組成物及び方法

Japanese Patent JP2002524415

A

This invention relates to the use of enantiomerically pure R-NSAIDs for the treatment of inflammation. Preferably, the R-NSAID used is R-flurbiprofen and is administered in a dose of at least 5 milligrams per kilogram of body weight per day. The anti-inflammatory action of R-NSAIDs is due to their ability to interfere with the biosynthesis of COX-2 by inhibiting COX-2 mRNA synthesis, rather than by just blocking the action of the enzyme itself. In order to effect the inhibition of COX-2 mRNA synthesis, the R-NSAID must be present at relatively high doses. Because the R-NSAID is selective in its action, that is, it does not inhibit either COX-1 mRNA synthesis or the COX-1 enzyme itself, it can be administered in the required high doses because the tissue protective effects of prostaglandins made through the COX-1 pathway are not interfered with.

Wector William Jay

JP2000568493A

August 06, 2002

September 03, 1999

Click for automatic bibliography generation  

Roma Linda University Medical Center

A61K45/00; A61K31/192; A61K31/381; A61K31/402; A61K31/403; A61K31/407; A61K31/423; A61P29/00; (IPC1-7): A61K45/00; A61K31/192; A61P29/00

JPN6009067488; Ａｇｅｎｔｓ　ａｎｄ　Ａｃｔｉｏｎｓ．　Ｓｕｐｐｌｅｍｅｎｔｓ Ｖｏｌ．４４, 1993, ｐ３１-３６
JPN5002007813; Ｅｘｐｅｒｉｅｎｔｉａ Ｖｏｌ．４７，Ｎｏ．３, 1991, ｐ２５７-２６１
JPN6009067491; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．３６，Ｎｏ．６, 1996, ｐ５１３-５２０
JPN6009067488; Ａｇｅｎｔｓ　ａｎｄ　Ａｃｔｉｏｎｓ．　Ｓｕｐｐｌｅｍｅｎｔｓ Ｖｏｌ．４４, 1993, ｐ３１-３６
JPN5002007813; Ｅｘｐｅｒｉｅｎｔｉａ Ｖｏｌ．４７，Ｎｏ．３, 1991, ｐ２５７-２６１
JPN6009067491; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．３６，Ｎｏ．６, 1996, ｐ５１３-５２０

Minoru Nakamura (9 outside)

Previous Patent: ３つの機能層を有する薬物硬膏剤

Next Patent: 持続放出型ラノラジン製剤